|
Comparisons (vs LODDS0)
|
OS
|
DFS
|
|---|
|
No. of studies
|
HR (95% CI)
|
Heterogeneity
|
No. of studies
|
HR (95% CI)
|
Heterogeneity
|
|---|
|
I2 (%)
|
I2 (%)
|
|---|
|
TOTAL studies
|
|
LODDS1
|
9
|
1.77 (1.38, 2.28)
|
18.3
|
4
|
1.82 (1.23, 2.68)
|
35
|
|
LODDS2
|
9
|
3.49 (2.88, 4.23)
|
0
|
3
|
4.53 (3.14, 6.55)
|
0
|
|
Yearc
|
|
> Median
|
|
LODDS1
|
4
|
1.53 (1.07, 2.21)
|
25.9
|
1
|
2.73 (1.72, 4.34)
|
–
|
|
LODDS2
|
4
|
3.51 (2.59, 4.76)
|
0
|
1
|
4.56 (2.91, 7.16)
|
–
|
|
≤ Median
|
|
LODDS1
|
5
|
2.06 (1.46, 2.92)
|
7.1
|
3
|
1.44 (0.99, 2.09)
|
0
|
|
LODDS2
|
5
|
3.62 (2.56, 5.11)
|
36.4
|
2
|
4.48 (2.36, 8.47)
|
0
|
|
Country
|
|
East Asia
|
|
LODDS1
|
2
|
2.41 (1.27, 4.57)
|
0
|
2
|
1.94 (0.97, 3.86)
|
74.6
|
|
LODDS2
|
2
|
3.65 (2.37, 5.62)
|
0
|
1
|
4.56 (2.91, 7.16)
|
–
|
|
non-East Asia
|
|
LODDS1
|
7
|
1.69 (1.27, 4.57)
|
26.4
|
2
|
1.54 (0.89, 2.67)
|
0
|
|
LODDS2
|
7
|
3.47 (2.78, 4.34)
|
4.9
|
2
|
4.48 (2.36, 8.47)
|
0
|
|
Type of cancer
|
|
colorectal cancer
|
|
LODDS1
|
3
|
2.21 (1.45, 3.37)
|
0
|
1
|
1.54 (0.89, 2.67)
|
–
|
|
LODDS2
|
3
|
3.48 (2.51, 4.84)
|
0
|
1
|
4.56 (2.91, 7.16)
|
–
|
|
colon cancer
|
|
LODDS1
|
5
|
1.68 (1.14, 2.46)
|
42.8
|
2
|
2.73 (1.72, 4.34)
|
0
|
|
LODDS2
|
5
|
3.79 (2.79, 5.15)
|
31
|
2
|
4.48 (2.36, 8.47)
|
0
|
|
rectal cancer
|
|
LODDS1
|
1
|
1.14 (0.44, 2.98)
|
–
|
1
|
1.35 (0.80, 2.26)
|
–
|
|
LODDS2
|
1
|
2.47 (1.17, 5.22)
|
–
|
–
|
–
|
–
|
- Abbreviations: CRC Colorectal cancer, HR Hazard ratio, OS Overall survival, DFS Disease-free survival, LODDS Log odds of positive lymph nodes
- “-”: not available
- aP-value for estimates of HR
- bP-value for heterogeneity
- cThe median year of OS, and DFS was 2017, and 2018, respectively
